Novartis AG (NVS)
167.11
+2.41
(+1.46%)
USD |
NYSE |
Feb 24, 16:00
167.11
0.00 (0.00%)
After-Hours: 16:19
Novartis Research and Development Expense (Quarterly) : 2.837B for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Amgen, Inc. | 2.151B |
| AstraZeneca PLC | 3.725B |
| Gilead Sciences, Inc. | 1.565B |
| Regeneron Pharmaceuticals, Inc. | 1.481B |